Imdelltra (tarlatamab)

pCPA File Number: 23046

Negotiation Status:

Under consideration for negotiation

Indication(s):

For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy

Sponsor/Manufacturer:

Amgen Canada Inc.

CDA-AMC Project Number:

PC0351-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable